Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

9 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

9 recruiting2 with results

Enrollment Performance

Analytics

Phase 3
8(66.7%)
Phase 1
3(25.0%)
Phase 4
1(8.3%)
12Total
Phase 3(8)
Phase 1(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07118215Phase 1Recruiting

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Role: lead

NCT06585787Phase 3Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Role: lead

NCT05980949Phase 3Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Role: lead

NCT06126224Phase 3Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Role: lead

NCT07424404Phase 3Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

Role: lead

NCT05145413Phase 3Completed

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Role: lead

NCT05511363Phase 3Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Role: lead

NCT05304767Phase 3Recruiting

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Role: lead

NCT06729970Phase 1Completed

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Role: lead

NCT07204418Phase 1Recruiting

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

Role: lead

NCT07257120Phase 4Recruiting

KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

Role: lead

NCT05919823Phase 3Completed

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

Role: lead

All 12 trials loaded